Skip to content
ppharmaranks
Menu

Depo-Provera Lawsuit

medroxyprogesterone acetate · Pfizer · updated June 2026

Depo-Provera, the long-acting birth-control shot, faces thousands of lawsuits alleging that long-term use raises the risk of meningioma (a brain tumor). The FDA has added a meningioma warning to the label.

This page is general information about ongoing litigation and FDA safety actions — not medical or legal advice, and not a statement that Depo-Provera caused any injury. Allegations described here are claims that have not been proven in court. Always consult a licensed professional.

What the lawsuits allege

Plaintiffs allege Pfizer failed to warn that repeated, long-term use of the medroxyprogesterone acetate shot increases the risk of developing a meningioma.

  • Meningioma (brain tumor)

FDA action

The FDA updated the Depo-Provera label to add a meningioma warning, reflecting cases reported with long-term use.

Verify against the current FDA-approved label: Depo-Provera label on DailyMed (U.S. NLM).

Where the litigation stands

As of mid-2026, several thousand meningioma claims are consolidated in a federal MDL. Bellwether trial dates have been in flux — treat any specific date as subject to change — and reports in June 2026 indicate Pfizer agreed to settle claims filed in the MDL.

Case counts and MDL status are published by the U.S. Judicial Panel on Multidistrict Litigation — JPML pending MDLs. Any figure not on the court record is attributed to the secondary legal-press links below.

Who may be affected

The Depo-Provera lawsuits are brought by people who say they used Depo-Provera (medroxyprogesterone acetate) and were later diagnosed with one or more of the alleged injuries above. Whether any individual situation could support a claim depends on the specific facts, the medical records, and each state's filing deadline (statute of limitations) — which can expire, so timing matters. Only a licensed attorney can evaluate a specific case. This page is general information, not legal advice.

Frequently asked

What is the Depo-Provera lawsuit about?
Plaintiffs allege Pfizer failed to warn that repeated, long-term use of the medroxyprogesterone acetate shot increases the risk of developing a meningioma. As of mid-2026, several thousand meningioma claims are consolidated in a federal MDL. Bellwether trial dates have been in flux — treat any specific date as subject to change — and reports in June 2026 indicate Pfizer agreed to settle claims filed in the MDL.
What injuries are alleged in the Depo-Provera lawsuits?
Lawsuits allege meningioma (brain tumor). These are allegations; a court has not found that Depo-Provera causes them.
Has the FDA acted on Depo-Provera?
The FDA updated the Depo-Provera label to add a meningioma warning, reflecting cases reported with long-term use.
Is there a deadline to file a Depo-Provera lawsuit?
Yes — every state sets a filing deadline (statute of limitations) for product-injury claims, often running from the date of injury or diagnosis, and once it passes a claim is usually barred. The exact window varies by state and circumstances, so anyone considering a claim should check with a licensed attorney promptly. This is general information, not legal advice.

Our independent rating

Other drug-safety & lawsuit trackers

See all safety & litigation trackers →

Sources